Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.19M | -86.46M | -74.18M | -53.26M | -131.21M |
| Total Depreciation and Amortization | 930.00K | 914.00K | 942.00K | 939.00K | 1.03M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.45M | 8.15M | 4.80M | -23.29M | 54.40M |
| Change in Net Operating Assets | -3.79M | -1.76M | -6.48M | -3.30M | -4.96M |
| Cash from Operations | -82.50M | -79.16M | -74.92M | -78.91M | -80.74M |
| Capital Expenditure | -437.00K | -373.00K | -206.00K | -104.00K | -130.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.39M | -15.46M | -52.91M | 26.40M | -18.15M |
| Cash from Investing | -37.83M | -15.83M | -53.12M | 26.30M | -18.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14.00K | -54.00K | -49.00K | -64.00K | -83.00K |
| Issuance of Common Stock | 101.87M | 101.88M | 101.88M | 102.18M | 438.00K |
| Repurchase of Common Stock | -219.00K | -219.00K | -176.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 101.64M | 101.61M | 101.66M | 102.12M | 355.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.69M | 6.62M | -26.38M | 49.51M | -98.67M |